Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo, 11562, Egypt.
Inflammopharmacology. 2023 Jun;31(3):1053-1067. doi: 10.1007/s10787-023-01216-x. Epub 2023 Apr 17.
Nociplastic pain is the third classification of pain as described by the International Association for the Study of Pain (IASP), in addition to the neuropathic and nociceptive pain classes. The main pathophysiological mechanism for developing nociplastic pain is central sensitization (CS) in which pain amplification and hypersensitivity occur. Fibromyalgia is the prototypical nociplastic pain disorder, characterized by allodynia and hyperalgesia. Much scientific data suggest that classical activation of microglia in the spinal cord mediates neuroinflammation which plays an essential role in developing CS. In this review article, we discuss the impact of microglia activation and M1/M2 polarization on developing neuroinflammation and nociplastic pain, besides the molecular mechanisms engaged in this process. In addition, we mention the impact of microglial modulators on M1/M2 microglial polarization that offers a novel therapeutic alternative for the management of nociplastic pain disorders. Illustrating the mechanisms underlying microglia activation in central sensitization and nociplastic pain. LPS lipopolysaccharide, TNF-α tumor necrosis factor-α, INF-γ Interferon gamma, ATP adenosine triphosphate, 49 P2Y12/13R purinergic P2Y 12/13 receptor, P2X4/7R purinergic P2X 4/7 receptor, SP Substance P, NK-1R Neurokinin 1 receptor, CCL2 CC motif ligand 2, CCR2 CC motif ligand 2 receptor, CSF-1 colony-stimulating factor 1, CSF-1R colony-stimulating factor 1 receptor, CX3CL1 CX3C motif ligand 1, CX3XR1 CX3C motif ligand 1 receptor, TLR toll-like receptor, MAPK mitogen-activated protein kinases, JNK jun N-terminal kinase, ERK extracellular signal-regulated kinase, iNOS Inducible nitric oxide synthase, IL-1β interleukin-1β, IL-6 interleukin-6, BDNF brain-derived neurotrophic factor, GABA γ-Aminobutyric acid, GABAR γ-Aminobutyric acid receptor, NMDAR N-methyl-D-aspartate receptor, AMPAR α-amino-3-hydroxy-5-methyl-4-isoxazolepropi-onic acid receptor, IL-4 interleukin-4, IL-13 interleukin-13, IL-10 interleukin-10, Arg-1 Arginase 1, FGF fibroblast growth factor, GDNF glial cell-derived neurotrophic factor, IGF-1 insulin-like growth factor-1, NGF nerve growth factor, CD Cluster of differentiation.
痛觉过敏是国际疼痛研究协会 (IASP) 描述的第三种疼痛分类,除此之外还有神经性疼痛和伤害性疼痛。痛觉过敏的主要病理生理机制是中枢敏化 (CS),在此过程中会发生疼痛放大和过敏。纤维肌痛是典型的痛觉过敏疼痛障碍,其特征是痛觉过敏和痛觉超敏。大量科学数据表明,脊髓中小胶质细胞的经典激活介导了神经炎症,在 CS 的发展中起着至关重要的作用。在这篇综述文章中,我们讨论了小胶质细胞激活以及 M1/M2 极化对神经炎症和痛觉过敏发展的影响,以及参与这一过程的分子机制。此外,我们还提到了小胶质细胞调节剂对 M1/M2 小胶质细胞极化的影响,这为痛觉过敏障碍的治疗提供了一种新的选择。阐述了小胶质细胞激活在中枢敏化和痛觉过敏中的机制。LPS 脂多糖,TNF-α 肿瘤坏死因子-α,INF-γ 干扰素-γ,ATP 三磷酸腺苷,49 P2Y12/13R 嘌呤能 P2Y12/13 受体,P2X4/7R 嘌呤能 P2X4/7 受体,SP 物质 P,NK-1R 神经激肽 1 受体,CCL2 CC 基序配体 2,CCR2 CC 基序配体 2 受体,CSF-1 集落刺激因子 1,CSF-1R 集落刺激因子 1 受体,CX3CL1 CX3C 基序配体 1,CX3XR1 CX3C 基序配体 1 受体,TLR toll 样受体,MAPK 丝裂原活化蛋白激酶,JNK Jun N-末端激酶,ERK 细胞外信号调节激酶,iNOS 诱导型一氧化氮合酶,IL-1β 白细胞介素-1β,IL-6 白细胞介素-6,BDNF 脑源性神经营养因子,GABA γ-氨基丁酸,GABAR γ-氨基丁酸受体,NMDAR N-甲基-D-天冬氨酸受体,AMPA α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体,IL-4 白细胞介素-4,IL-13 白细胞介素-13,IL-10 白细胞介素-10,Arg-1 精氨酸酶 1,FGF 成纤维细胞生长因子,GDNF 胶质细胞源性神经营养因子,IGF-1 胰岛素样生长因子-1,NGF 神经生长因子,CD 分化群。